Dermata Therapeutics Net Worth
Dermata Therapeutics Net Worth Breakdown | DRMA |
Dermata Therapeutics Net Worth Analysis
Dermata Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dermata Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dermata Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dermata Therapeutics' net worth analysis. One common approach is to calculate Dermata Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dermata Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dermata Therapeutics' net worth. This approach calculates the present value of Dermata Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dermata Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dermata Therapeutics' net worth. This involves comparing Dermata Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dermata Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Dermata Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dermata Therapeutics' net worth research are outlined below:
| Dermata Therapeutics generated a negative expected return over the last 90 days | |
| Dermata Therapeutics has high historical volatility and very poor performance | |
| Dermata Therapeutics may become a speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics Inc |
Dermata Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dermata Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dermata Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Dermata Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dermata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dermata Therapeutics backward and forwards among themselves. Dermata Therapeutics' institutional investor refers to the entity that pools money to purchase Dermata Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-06-30 | 1.7 K | Ubs Group Ag | 2024-06-30 | 1.7 K | Wells Fargo & Co | 2024-06-30 | 45.0 | Bank Of America Corp | 2024-06-30 | 3.0 | Acadian Asset Management Llc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-06-30 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 0.0 |
Follow Dermata Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.25 M.Market Cap |
|
Project Dermata Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.27) | (1.33) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.23) | (1.29) |
When accessing Dermata Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dermata Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dermata Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Dermata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dermata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dermata Therapeutics' management manipulating its earnings.
Evaluate Dermata Therapeutics' management efficiency
Dermata Therapeutics has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7301) %, meaning that it created substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -1.03. In addition to that, Return On Capital Employed is expected to decline to -1.33. At present, Dermata Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.53, whereas Total Assets are forecasted to decline to about 6.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.76 | 34.40 | |
| Tangible Book Value Per Share | 32.76 | 34.40 | |
| Enterprise Value Over EBITDA | (20.62) | (21.65) | |
| Price Book Value Ratio | 0.28 | 0.29 | |
| Enterprise Value Multiple | (20.62) | (21.65) | |
| Price Fair Value | 0.28 | 0.29 | |
| Enterprise Value | 70.8 M | 67.2 M |
Dermata Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Return On Equity (1.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scott Kathleen D. over six months ago Acquisition by Scott Kathleen D. of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Sandler Andrew Seth over six months ago Acquisition by Sandler Andrew Seth of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Gerald Proehl over six months ago Acquisition by Gerald Proehl of 27987 shares of Dermata Therapeutics at 20.5 subject to Rule 16b-3 | ||
Gerald Proehl over six months ago Dermata Therapeutics exotic insider transaction detected | ||
Nardo Christopher J over a year ago Acquisition by Nardo Christopher J of 100000 shares of Dermata Therapeutics subject to Rule 16b-3 |
Dermata Therapeutics Earnings per Share Projection vs Actual
Dermata Therapeutics Corporate Management
| Maria MBA | Senior Assurance | Profile | |
| Gerald Proehl | President, Founder | Profile | |
| Sean Proehl | Senior Development | Profile | |
| David Hale | CoFounder Director | Profile | |
| Dr MPH | Senior Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.36) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.